Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.60 |
| ▸ | CALCRL | Q16602 | 18/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.53 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709149 | 0.92 | CALCA (0.69) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL4033359 | 0.92 | CALCA (0.69) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL3876080 | 0.92 | CALCA (0.71) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL3873446 | 0.91 | CALCA (0.61) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL3277851 | 0.89 | CALCRL (0.57) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL3277861 | 0.89 | CALCRL (0.57) | CALCACALCRLCYP3A4RAMP1 | |
| SCHEMBL3278050 | 0.88 | CALCA (0.53) | CALCACALCRLCYP3A4RAMP1POLB | |
| SCHEMBL3278354 | 0.88 | CALCA (0.53) | CALCACALCRLCYP3A4RAMP1POLB | |
| SCHEMBL3311076 | 0.85 | CALCA (0.67) | CALCACALCRLCYP3A4 | |
| SCHEMBL3884981 | 0.84 | CALCRL (0.45) | CALCACALCRLCYP3A4RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538115-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1487821-B1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-7026312-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-29 | — | — | US | disclosed |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX5, CALCRL, ADRA1D | CALCA 6/4885CALCRL 2/4885CYP3A4 1373/4885 |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX3, P2RX5, P2RX2 | CALCA 16/4885CALCRL 8/4885CYP3A4 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.